Evidence map›Paper›PMID 27869160›Full record

ArticleOncogene2017

Pot1 OB-fold mutations unleash telomere instability to initiate tumorigenesis.

P Gu, Y Wang, K K Bisht, L Wu, L Kukova, E M Smith, Y Xiao, S M Bailey, M Lei, J Nandakumar and 1 more

Abstract read
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 63 citations in OpenAlex.

  1. How telomere attrition protects against cancer.Nature reviews. Genetics · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. GermlineGenes · 2024
    Review
  10. Article
  11. HGG advances · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Frontiers in veterinary science · 2022
    Article
  17. Article
  18. MITOCHONDRIAL CHOLESTEROL AND CANCER.Seminars in cancer biology · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

P GuDepartment of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.
Y WangDepartment of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.
K K BishtDepartment of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, MI, USA.
L WuDepartment of GI Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA.
L KukovaDepartment of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.
E M SmithDepartment of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, MI, USA.
Y XiaoSection of Hematology-Oncology, Department of Medicine and Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
S M BaileyDepartment of Environmental & Radiological Health Sciences, Colorado State University, Fort Collins, CO, USA.
M LeiNational Center for Protein Science Shanghai, State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
J NandakumarDepartment of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, MI, USA.
S ChangDepartment of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.
Yale University · USUniversity of Michigan–Ann Arbor · USBaylor College of Medicine · USColorado State University · USShanghai Institutes for Biological Sciences · CNThe University of Texas MD Anderson Cancer Center · US

Funding

Research Training in BiogerontologyT32AG000114 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCOTT PLETCHER · 1985 to 2026
$12.4M
Telomere induced senescence as a supressor of tumorigenesisR01CA129037 · NCI · YALE UNIVERSITY · PI CHANG, SANDY S · 2007 to 2017
$3.1M
Molecular functions of the shelterin component ACD/TPP1 in somatic stem cells and tissue homeostasisR01AG050509 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KEEGAN, CATHERINE ELIZABETH, MAILLARD, IVAN · 2015 to 2019
$2.3M
Telomere dysfunction induced breast cancer pathogenesisR01CA202816 · NCI · YALE UNIVERSITY · PI CHANG, SANDY S · 2016 to 2020
$1.9M
The role fo the TPP1 peotein in telomerase function and cancer cell survivalR00CA167644 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NANDAKUMAR, JAYAKRISHNAN · 2013 to 2015
$689k
Telomere dysfunction and genome instability in familial melanomaR21CA200506 · NCI · YALE UNIVERSITY · PI CHANG, SANDY S · 2016 to 2017
$400k
Understanding alternative non-homologous end joining repair in telomere dysfunctiR21CA182280 · NCI · YALE UNIVERSITY · PI CHANG, SANDY S · 2014 to 2015
$398k
NCI NIH HHS R00 CA167644NCI NIH HHS R01 CA129037NCI NIH HHS R01 CA202816NCI NIH HHS R21 CA182280NCI NIH HHS R21 CA200506NIA NIH HHS R01 AG050509NIA NIH HHS T32 AG000114
6 · The paper itself

Abstract

Chromosomal aberrations are a hallmark of human cancers, with complex cytogenetic rearrangements leading to genetic changes permissive for cancer initiation and progression. Protection of Telomere 1 (POT1) is an essential component of the shelterin complex and functions to maintain chromosome stability by repressing the activation of aberrant DNA damage and repair responses at telomeres. Sporadic and familial mutations in the oligosaccharide-oligonucleotide (OB) folds of POT1 have been identified in many human cancers, but the mechanism underlying how hPOT1 mutations initiate tumorigenesis has remained unclear. Here we show that the human POT1's OB-folds are essential for the protection of newly replicated telomeres. Oncogenic mutations in hPOT1 OB-fold fail to bind to single-stranded telomeric DNA, eliciting a DNA damage response at telomeres that promote inappropriate chromosome fusions via the mutagenic alternative non-homologous end joining (A-NHEJ) pathway. hPOT1 mutations also result in telomere elongation and the formation of transplantable hematopoietic malignancies. Strikingly, conditional deletion of both mPot1a and p53 in mouse mammary epithelium resulted in development of highly invasive breast carcinomas and the formation of whole chromosomes containing massive arrays of telomeric fusions indicative of multiple breakage-fusion-bridge cycles. Our results reveal that hPOT1 OB-folds are required to protect and prevent newly replicated telomeres from engaging in A-NHEJ mediated fusions that would otherwise promote genome instability to fuel tumorigenesis.

Indexed as

MutationAnimalsCarcinogenesisCells, CulturedChromosomal InstabilityChromosome AberrationsDNA End-Joining RepairHEK293 CellsHeLa CellsHumansMiceMice, KnockoutMice, SCIDOligonucleotidesOligosaccharidesShelterin ComplexOligonucleotidesOligosaccharidesPOT1 protein, humanShelterin ComplexTelomere-Binding Proteins

Identifiers

PMID27869160
PMCPMC5383532
OpenAlexW2554700777

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.